McCarthy Anne Marie, Kontos Despina, Synnestvedt Marie, Tan Kay See, Heitjan Daniel F, Schnall Mitchell, Conant Emily F
Division of General Internal Medicine (AMM, MS), Department of Radiology (DK, MS, EFC), and Department of Biostatistics and Epidemiology (KST, DFH), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; General Medicine Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA (AMM).
J Natl Cancer Inst. 2014 Oct 13;106(11). doi: 10.1093/jnci/dju316. Print 2014 Nov.
Early data on breast cancer screening utilizing digital breast tomosynthesis (DBT) combined with digital mammography (DM) have shown improvements in false-positive and false-negative screening rates compared with DM alone. However, these trials were performed at sites where conventional mammographic screening was concurrently performed, possibly leading to selection biases or with complex, multireader algorithms not reflecting general clinical practice. Our study reports the impact on screening outcomes for DBT screening implemented in an entire clinic population.
Recall rates, cancer detection, and positive predictive values of screening were compared for 15571 women screened with DBT and 10728 screened with DM alone prior to DBT implementation at a single breast imaging center. Generalized linear mixed-effects models were used to estimate the odds ratio (OR) for recall rate adjusted for age, race, presence of prior mammograms, breast density and reader. All statistical tests were two-sided.
DBT screening showed a statistically significant reduction in recalls compared to DM alone. For the entire population, there were 16 fewer recalls (8.8% vs 10.4%, P <.001, adjusted OR = 0.80, 95% confidence interval [CI] = 0.74 to 0.88, P < .001) and 0.9 additional cancers detected per 1000 screened with DBT compared to DM alone. There was a statistically significant increase in PPV1 (6.2% vs 4.4%, P = .047). In women younger than age 50 years screened with DBT, there were 17 fewer recalls (12.3% vs 14.0%, P = .02) and 3.6 additional cancer detected per 1000 screened (5.7 vs 2.2 per 1000, P = .02).
Our data support the clinical implementation of DBT in breast cancer screening; however, larger prospective trials are needed to validate our findings in specific patient subgroups.
早期关于利用数字乳腺断层合成(DBT)联合数字乳腺钼靶摄影(DM)进行乳腺癌筛查的数据显示,与单纯DM相比,假阳性和假阴性筛查率有所改善。然而,这些试验是在同时进行传统乳腺钼靶筛查的地点进行的,这可能导致选择偏倚,或者采用的复杂多阅片者算法不能反映一般临床实践。我们的研究报告了在整个临床人群中实施DBT筛查对筛查结果的影响。
在一个乳腺影像中心,比较了15571名接受DBT筛查的女性和10728名在实施DBT之前单纯接受DM筛查的女性的召回率、癌症检出率和筛查阳性预测值。采用广义线性混合效应模型估计经年龄、种族、既往乳腺钼靶检查情况、乳腺密度和阅片者校正后的召回率比值比(OR)。所有统计检验均为双侧检验。
与单纯DM相比,DBT筛查的召回率在统计学上显著降低。在整个人群中,与单纯DM相比,DBT筛查的召回次数减少了16次(8.8%对10.4%,P<.001,校正OR = 0.80,95%置信区间[CI] = 0.74至0.88,P<.001),每1000名接受DBT筛查的女性中额外检出0.9例癌症。PPV1有统计学显著增加(6.2%对4.4%,P = .047)。在年龄小于50岁且接受DBT筛查的女性中,召回次数减少了17次(12.3%对14.0%,P = .02),每1000名接受筛查的女性中额外检出3.6例癌症(每1000名中5.7例对2.2例,P = .02)。
我们的数据支持在乳腺癌筛查中临床应用DBT;然而,需要更大规模的前瞻性试验来验证我们在特定患者亚组中的研究结果。